Targeting gut microbiota-derived kynurenine to predict and protect the remodeling of the pressure-overloaded young heart

Sci Adv. 2023 Jul 14;9(28):eadg7417. doi: 10.1126/sciadv.adg7417. Epub 2023 Jul 14.

Abstract

Pressure-overloaded left ventricular remodeling in young population is progressive and readily degenerate into heart failure. The aims of this study were to identify a plasma metabolite that predicts and is mechanistically linked to the disease. Untargeted metabolomics determined elevated plasma kynurenine (Kyn) in both the patient cohorts and the mice model, which was correlated with remodeling parameters. In vitro and in vivo evidence, combined with single-nucleus RNA sequencing (snRNA-seq), demonstrated that Kyn affected both cardiomyocytes and cardiac fibroblasts by activating aryl hydrocarbon receptors (AHR) to up-regulate hypertrophy- and fibrosis-related genes. Shotgun metagenomics and fecal microbiota transplantation revealed the existence of the altered gut microbiota-Kyn relationship. Supplementation of selected microbes reconstructed the gut microbiota, reduced plasma Kyn, and alleviated ventricular remodeling. Our data collectively discovered a gut microbiota-derived metabolite to activate AHR and its gene targets in remodeling young heart, a process that could be prevented by specific gut microbiota modulation.

MeSH terms

  • Animals
  • Fibroblasts / metabolism
  • Gastrointestinal Microbiome*
  • Heart
  • Kynurenine* / metabolism
  • Metabolomics
  • Mice

Substances

  • Kynurenine